Companies Spero Therapeutics, Inc.
Spero Therapeutics CEO salary & total pay, FY2025: $2.1M
Spero Therapeutics (SPRO) CEO salary, fiscal 2025: Esther Rajavelu was paid a salary of $577,179 and $2,061,496 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Spero Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Esther Rajavelu's complete compensation dossier
A PDF and a CSV sent to your email: Esther Rajavelu's pay in every fiscal year Spero Therapeutics, Inc. reported it, line by line, with Esther Rajavelu's equity grants and Spero Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $2,385,905FY2023
- $856,479FY2024
- $2,061,496FY2025
CEO total pay was $2,061,496 in fiscal 2025, up from $856,479 in fiscal 2024.
FY2025: salary $577,179 · bonus $687,479 · stock awards $413,705 · option awards $0
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Esther Rajavelu | $577,179 | $687,479 | $413,705 | $0 | $372,000 | $0 | $11,134 | $2,061,496 |
| President and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer(5) | ||||||||
| Satyavrat Shukla | 244,153 | 452,813 | 603,380 | 0 | 307,912 | 0 | 416,919 | 2,025,178 |
| Former President and Chief Executive Officer(6) | ||||||||
| Tim Keutzer | 484,566 | 498,818 | 213,710 | 0 | 232,592 | 0 | 11,134 | 1,440,820 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Esther Rajavelu | $2,061,496 | $856,479 | — | ↑ +1,205,017 |
| Satyavrat Shukla | 2,025,178 | 1,953,237 | 2,024,647 | ↑ +71,941 |
| Tim Keutzer | 1,440,820 | 1,033,450 | — | ↑ +407,370 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Meridian Compensation Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Esther Rajavelu | RSU | — | 150,000 | — | $349,500 |
| Esther Rajavelu | RSU | — | 89,899 | — | 209,465 |
| Esther Rajavelu | RSU | — | 366,139 | — | 853,104 |
| Esther Rajavelu | RSU | — | 185,000 | — | 431,050 |
| Tim Keutzer | Option | 50,974 | 2,216 | 11.18 | — |
| Tim Keutzer | RSU | — | 9,503 | — | 22,142 |
| Tim Keutzer | RSU | — | 132,978 | — | 309,839 |
| Tim Keutzer | RSU | — | 179,798 | — | 418,929 |
| Tim Keutzer | RSU | — | 266,139 | — | 620,104 |
| Tim Keutzer | Option | 55,943 | — | 5.9 | — |
| Tim Keutzer | Option | 25,016 | — | 11.63 | — |
| Tim Keutzer | Option | 25,000 | — | 6.26 | — |
| Tim Keutzer | Option | 55,000 | — | 9.34 | — |
| Tim Keutzer | Option | 57,432 | — | 19.18 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John C. Pottage Jr., M.DNot independent · Development (Chair) | $50,000 | $57,800 | — | — | $225,000 | $332,800 |
| Frank E. ThomasIndependent · Board Chair | 130,000 | 57,800 | — | — | 0 | 187,800 |
| Patrick Vink, M.DIndependent · Nominating and Corporate Governance (Chair) · Compensation | 83,750 | 57,800 | — | — | 0 | 141,550 |
| Milind Deshpande, Ph.DIndependent · Audit · Nominating and Corporate Governance · Development | 62,500 | 57,800 | — | — | 0 | 120,300 |
| Cynthia SmithIndependent · Compensation (Chair) | 60,000 | 57,800 | — | — | 0 | 117,800 |
| Scott JacksonIndependent · Audit · Nominating and Corporate Governance | 57,500 | 57,800 | — | — | 0 | 115,300 |
| Kathleen TregoningIndependent · Compensation | 50,000 | 57,800 | — | — | 0 | 107,800 |
| Ankit Mahadevia, M.DNot independent · Development | 45,000 | 57,800 | — | — | 0 | 102,800 |
| Esther RajaveluEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $20,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 15,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $538,750 |
| Equity awards (grant-date value) | $462,400 |
| All other compensation | $225,000 |
| Total cost of the board | $1,226,150 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Spero Therapeutics as a peer
Companies that benchmark against SPRO
1 company names SPRO as a compensation peer
- ASSEMBLY BIOSCIENCES, INC.ASMBFY2025
- Seres Therapeutics, Inc.MCRBFY2025
Each company listed discloses SPRO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SPRO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Spero Therapeutics, Inc. | 2025 | Esther Rajavelu | $577,179 | $413,705 | $0 | $372,000 | $2,061,496 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-23 | 27,890,254 | 1,002,982 | 107,174 | 96.53% | Passed |
| 2025 | 2025-06-12 | 25,178,672 | 638,744 | 354,784 | 97.53% | Passed |
| 2024 | 2024-05-29 | 23,890,281 | 442,014 | 404,371 | 98.18% | Passed |
| 2023 | 2023-10-05 | 20,123,647 | 1,145,027 | 259,285 | 94.62% | Passed |
| 2022 | 2022-09-15 | — | — | — | — | — |
| 2021 | 2021-08-17 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-23 | 96.53%a |
| 2025 | 2025-06-12 | 97.53%b |
| 2024 | 2024-05-29 | 98.18%c |
a. Approved under the standard stated in the filing — “Proposal 2: Ratify Appointment of Independent Registered Public Accounting Firm The affirmative vote of the holders of a majority in voting power of the votes cast by the holders of the shares of our common stock present or represented at the meeting and voting affirmatively or negatively for this proposal is required to ratify the appointment of our independent registered public accounting firm. || Abstentions: Abstentions will have no effect on the results of this vote.”.
b. Approved under the standard stated in the filing — “Proposal 3: Advisory Vote on Compensation of the Company's Named Executive Officers The affirmative vote of a majority in voting power of the votes cast by the holders of the shares of our common stock present or represented at the meeting and voting affirmatively or negatively for this proposal is required to approve the advisory vote on the compensation of our named executive officers, as described in this proxy statement. || Abstentions: Abstentions will have no effect on the results of this vote.”.
c. Approved under the standard stated in the filing — “Abstentions will have no effect on the results of this vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Esther Rajavelu | See Remarks | 2026-05-04 | D | 25,240 | $3 | $63,352 | Common | Form 4 ↗ |
| Frank E. Thomas | Director | 2026-06-23 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank E. Thomas | Director | 2026-06-23 | A | 10,000 | 0 | 0 | Common | Form 4 ↗ |
| Kathleen Tregoning | Director | 2026-06-23 | A | 10,000 | 0 | 0 | Common | Form 4 ↗ |
| Cynthia Smith | Director | 2026-06-23 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cynthia Smith | Director | 2026-06-23 | A | 10,000 | 0 | 0 | Common | Form 4 ↗ |
| John C. Pottage Jr | Director | 2026-06-23 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John C. Pottage Jr | Director | 2026-06-23 | A | 10,000 | 0 | 0 | Common | Form 4 ↗ |
| Scott Jackson | Director | 2026-06-23 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Jackson | Director | 2026-06-23 | A | 10,000 | 0 | 0 | Common | Form 4 ↗ |
| Patrick V.j.j. Vink | Director | 2026-06-23 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick V.j.j. Vink | Director | 2026-06-23 | A | 10,000 | 0 | 0 | Common | Form 4 ↗ |
| Kathleen Tregoning | Director | 2026-06-23 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Milind Deshpande | Director | 2026-06-23 | A | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Milind Deshpande | Director | 2026-06-23 | A | 10,000 | 0 | 0 | Common | Form 4 ↗ |
| Debra Zack | Chief Medical Officer | 2026-08-03 | A | 324,675 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Debra Zack | Chief Medical Officer | 2026-08-03 | A | 162,311 | 0 | 0 | Common | Form 4 ↗ |
| Esther Rajavelu | Director | 2026-11-09 | D | 40,851 | 1 | 42,485 | Common | Form 4 ↗ |
| William Ho | Director | 2026-11-10 | A | 100,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (37 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Esther Rajavelu. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · page 23. As printed: 2,061,496. View filing ↗
- Section 01, Satyavrat Shukla. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 2,025,178. View filing ↗
- Section 01, Tim Keutzer. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 1,440,820. View filing ↗
- Section 08, John C. Pottage Jr., M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 332,800. View filing ↗
- Section 08, Frank E. Thomas. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 187,800. View filing ↗
- Section 08, Patrick Vink, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 141,550. View filing ↗
- Section 08, Milind Deshpande, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 120,300. View filing ↗
- Section 08, Cynthia Smith. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 117,800. View filing ↗
- Section 08, Scott Jackson. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 115,300. View filing ↗
- Section 08, Kathleen Tregoning. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 107,800. View filing ↗
- Section 08, Ankit Mahadevia, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 102,800. View filing ↗
- Section 08, Esther Rajavelu. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Esther Rajavelu 2026-05-04. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank E. Thomas 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank E. Thomas 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathleen Tregoning 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia Smith 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia Smith 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John C. Pottage Jr 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John C. Pottage Jr 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Jackson 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Jackson 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick V.j.j. Vink 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick V.j.j. Vink 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathleen Tregoning 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Milind Deshpande 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Milind Deshpande 2026-06-23. Form 4, filed 2026-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Zack 2026-08-03. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Debra Zack 2026-08-03. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Esther Rajavelu 2026-11-09. Form 4, filed 2026-11-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Ho 2026-11-10. Form 4, filed 2026-11-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-25. Item 5.07 · say-on-pay result. As reported: 96.53% (votes for as printed: 27,890,254). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-18. Item 5.07 · say-on-pay result. As reported: 97.53% (votes for as printed: 25,178,672). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-03. Item 5.07 · say-on-pay result. As reported: 98.18% (votes for as printed: 23,890,281). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 538,750 + equity 462,400 + all other 225,000 = 1,226,150, summed across the director compensation table rows.
- Spero Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Spero Therapeutics, Inc.'s own proxy. As printed: 2,061,496. View filing ↗